Renin-angiotensin system in intestinal inflammation-Angiotensin inhibitors to treat inflammatory bowel diseases?

Show full item record



Permalink

http://hdl.handle.net/10138/333883

Citation

Salmenkari , H , Korpela , R & Vapaatalo , H 2021 , ' Renin-angiotensin system in intestinal inflammation-Angiotensin inhibitors to treat inflammatory bowel diseases? ' , Basic & Clinical Pharmacology & Toxicology , vol. 129 , no. 3 , pp. 161-172 . https://doi.org/10.1111/bcpt.13624

Title: Renin-angiotensin system in intestinal inflammation-Angiotensin inhibitors to treat inflammatory bowel diseases?
Author: Salmenkari, Hanne; Korpela, Riitta; Vapaatalo, Heikki
Contributor: University of Helsinki, Clinicum
University of Helsinki, Riitta Anneli Korpela / Principal Investigator
University of Helsinki, Medicum
Date: 2021-09
Language: eng
Number of pages: 12
Belongs to series: Basic & Clinical Pharmacology & Toxicology
ISSN: 1742-7835
URI: http://hdl.handle.net/10138/333883
Abstract: Inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal tract, which manifest in recurring gastrointestinal inflammation. The current treatment options of IBD are not curative and are lacking in aspects like prevention of fibrosis. New treatment options are needed to fulfil the unmet needs and provide alternatives to drugs with resistances and side effects. Drugs targeting the renin-angiotensin system (RAS), besides being antihypertensive, also possess anti-inflammatory and antifibrotic properties and could offer an inexpensive alternative to control inflammation and fibrosis in the gut. RAS inhibitors have been effective in preventing and alleviating colitis in preclinical studies, but available human data are still sparse. This review outlines the pathophysiological functions of RAS in the gut and summarizes preclinical studies utilizing pharmacological RAS inhibitors in the treatment of experimental colitis. We discuss the alterations in intestinal RAS and the available evidence of the benefits of RAS inhibitors for IBD patients. Retrospective studies comparing IBD patients using ACE inhibitors or angiotensin II receptor blockers have provided optimistic results regarding a milder disease course and fewer hospitalizations and corticosteroid use in patients using RAS inhibitors. Prospective studies are needed to evaluate the effectiveness of these promising medications in the treatment of IBD.
Subject: ACE inhibitors
angiotensin II receptor blockers
colitis
inflammatory bowel diseases
renin-angiotensin system
CONVERTING ENZYME-INHIBITORS
II RECEPTOR ANTAGONIST
MOUSE COLITIS MODEL
COLONIC INFLAMMATION
CROHNS-DISEASE
TNF-ALPHA
TELMISARTAN
ACTIVATION
EXPRESSION
FIBROSIS
3111 Biomedicine
317 Pharmacy
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
bcpt.13624.pdf 728.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record